How to take vepotuzumab (POLIVY)

The recommended dose of vepotuzumab (POLIVY) is < span>1.8 mg/kg, in combination with rituximab products, cyclophosphamide, doxorubicin, and prednisone, as an intravenous infusion every 21 days for 6 cycles, with velpotuzumab, cyclophosphamide, doxorubicin, and rituximab products administered in any order on day 1 after prednisone, with prednisone administered on days 1-5 of each cycle.

For patients with relapsed or refractory diffuse largeB-cell lymphoma (DLBCL) , not otherwise specified (NOS) The recommended dose of velpotuzumab is 1.8 mg/kg in combination with bendamustine and rituximab as an intravenous infusion every 21 days for a total of 6 cycles. Administer velpotuzumab, bendamustine, and rituximab products in any order on Day 1 of each cycle. The recommended dose of bendamustine when administered with velpotuzumab and rituximab products is 90 mg/m2/day on Days 1 and 2. The recommended intravenous dose of rituximab product is 375 mg/m2 on Day 1 of each cycle.

Vepotolizumab's patent medicine has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. It is an injectable preparation. The price of 30 mg per box may be around RMB 10,000. The price of the Hong Kong version of 140 mg per box may be around RMB 60,000 (the price may fluctuate due to exchange rates) overseas. The price of the European version of vepotuzumab on the market, Specifications140 mg per box, may be around 90,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of domestic original drugs are basically the same as those of foreign original drugs, and they are expensive. There are currently no generic versions of vepotuzumab on the market.